Top

Published in:

01-03-2010

The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence

Authors: E. Galli, A. Pingitore, G. Iervasi

Published in: Heart Failure Reviews | Issue 2/2010

Abstract

Thyroid hormone (TH) has a fundamental role in cardiovascular homeostasis in both physiological and pathological conditions, influencing cardiac contractility, heart rate (HR), diastolic function and systemic vascular resistance (SVR) through genomic and non-genomic mediated effects. In heart failure (HF) the main alteration of thyroid function is referred to as “low-triiodothyronine (T3) syndrome” (LT3S) characterized by decreased total serum T3 and free T3 (fT3) with normal levels of thyroxine (T4) and thyrotropin (TSH). Even if commonly interpreted as an adaptive factor, LT3S may have potential negative effects, contributing to the progressive deterioration of cardiac function and myocardial remodeling in HF and representing a powerful predictor of mortality in HF patients. All these observations, together with the early evidence of the benefits of T3 administration in HF patients indicate that placebo-controlled prospective studies are now needed to better define the safety and prognostic effects of chronic treatment with synthetic TH in HF.

Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348:2007–2018. doi:10.1056/NEJMra021498 PubMed

Francis GS (2001) Pathophysiology of chronic heart failure. Am J Med 110(Suppl 7A):37S–46S. doi:10.1016/S0002-9343(98)00385-4 PubMed

Mann DL (1999) Mechanisms and models in heart failure—a combinatorial approach. Circulation 100:999–1008PubMed

Packer M (1992) The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. Am J Cardiol 20:248–254

Bleumink GS, Knetsch AM, Sturkenboom MC et al (2004) Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25:1614–1619. doi:10.1016/j.ehj.2004.06.038 PubMed

Klein I, Ojamaa K (2004) Thyroid hormone and the cardiovascular system. N Engl J Med 244:501–507

Kahaly GJ, Dillmann WH (2005) Thyroid hormone action in the heart. Endocr Rev 26:704–728. doi:10.1210/er.2003-0033 PubMed

Klein I, Danzi S (2007) Thyroid disease and the heart. Circulation 116:1725–1735. doi:10.1161/CIRCULATIONAHA.106.678326 PubMed

Iervasi G, Molinaro S, Landi P et al (2007) Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 167:1526–1532. doi:10.1001/archinte.167.14.1526 PubMed

10.

Hamilton MA, Stevenson LW, Luu M et al (1990) Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol 16:91–95PubMedCrossRef

11.

Ascheim DD, Hryniewicz K (2002) Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state. Thyroid 12:511–515. doi:10.1089/105072502760143908 PubMed

12.

Iervasi G, Pingitore A, Landi P et al (2003) Low-T3 syndrome—a strong prognostic predictor of death in patients with heart disease. Circulation 107:708–713. doi:10.1161/01.CIR.0000048124.64204.3F PubMed

13.

Pingitore A, Landi P, Taddei MC et al (2005) Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 118:132–136. doi:10.1016/j.amjmed.2004.07.052 PubMed

14.

Opasich C, Pacini F, Ambrosino N et al (1996) Sick euthyroid syndrome in patients with moderate-to-severe chronic heart failure. Eur Heart J 17:1860–1866PubMed

15.

Kozdag G, Ural D, Vural A et al (2005) Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy. Eur J Heart Fail 7:113–118. doi:10.1016/j.ejheart.2004.04.016 PubMed

16.

Pingitore A, Iervasi G, Barison A et al (2006) Early activation of an altered thyroid hormone profile in asymptomatic or mildly symptomatic idiopathic left ventricular dysfunction. J Card Fail 12:520–526. doi:10.1016/j.cardfail.2006.05.009 PubMed

17.

Pilo A, Iervasi G, Vitek F et al (1990) Thyroidal and peripheral production of 3, 5, 3′-triiodothyronine in humans by mental analysis. Am J Physiol 258:E715–E726PubMed

18.

Yen PM (2001) Physiological and molecular basis of thyroid hormone action. Physiol Rev 81:1097–1142PubMed

19.

Bianco AC, Salvatore D, Gereben B et al (2002) Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23:38–89. doi:10.1210/er.23.1.38 PubMed

20.

Everts ME, Verhoeven FA, Bezstarosti K et al (1996) Uptake of thyroid hormones in neonatal rat cardiac myocytes. Endocrinology 137:4235–4242. doi:10.1210/en.137.10.4235 PubMed

21.

Sabatino L, Iervasi G, Ferrazzi P et al (2000) A study of iodothyronine 5′-monodeiodinase activities in normal and pathological tissues in man and their comparison with activities in rat tissues. Life Sci 68:191–202. doi:10.1016/S0024-3205(00)00929-2 PubMed

22.

Wassen FW, Schiel AE, Kuiper GG et al (2002) Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. Endocrinology 143:2812–2815. doi:10.1210/en.143.7.2812 PubMed

23.

Simonides WS, Mulcahey MA, Redout EM et al (2008) Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. J Clin Invest 118:975–983PubMed

24.

Brent GA (1994) The molecular basis of thyroid hormone action. N Engl J Med 31:847–853. doi:10.1056/NEJM199409293311306

25.

Davis PJ, Davis FB (2002) Nongenomic actions of thyroid hormone on the heart. Thyroid 12:459–466. doi:10.1089/105072502760143827 PubMed

26.

Wrutniak-Cabello C, Casas F, Cabello G (2001) Thyroid hormone action in mitochondria. J Mol Endocrinol 26:67–77. doi:10.1677/jme.0.0260067 PubMed

27.

Bassett JH, Harvey CB, Williams GR (2003) Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Mol Cell Endocrinol 213:1–11. doi:10.1016/j.mce.2003.10.033 PubMed

28.

Lazar MA (1993) Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 14:184–193. doi:10.1210/er.14.2.184 PubMed

29.

Wu Y, Koenig RJ (2000) Gene regulation by thyroid hormone. Trends Endocrinol Metab 11:207–211. doi:10.1016/S1043-2760(00)00263-0 PubMed

30.

Shibusawa N, Hollenberg AN, Wondisford FE (2003) Thyroid hormone receptor DNA binding is required for both positive and negative gene regulation. J Biol Chem 278:732–738. doi:10.1074/jbc.M207264200 PubMed

31.

Lazar MA (2003) Thyroid hormone action: a binding contract. J Clin Invest 112:497–499PubMed

32.

Davis PJ, Shih A, Lin HY et al (2000) Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J Biochem 275:38032–38039

33.

Frank KF, Bölck B, Erdmann E et al (2003) Sarcoplasmic reticulum Ca2 + -ATPase modulates cardiac contraction and relaxation. Cardiovasc Res 57:20–27. doi:10.1016/S0008-6363(02)00694-6 PubMed

34.

Koss KL, Kranias EG (1996) Phospholamban: a prominent regulator of myocardial contractility. Circ Res 79:1059–1063PubMed

35.

Ojamaa K, Petrie JF, Balkman C (1994) Posttranscriptional modification of myosin heavy-chain gene expression in the hypertrophied rat myocardium. Proc Natl Acad Sci USA 91:3468–3472. doi:10.1073/pnas.91.8.3468 PubMed

36.

Klein I, Ojamaa K (2001) Thyroid hormone targeting the vascular smooth muscle cell. Circ Res 88:260–261PubMed

37.

Ojamaa K, Klemperer JD, Klein I (1996) Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 6:505–512PubMed

38.

Colantuoni A, Marchiafava PL, Lapi D et al (2005) Effects of tetraiodothyronine and triiodothyronine on hamster cheek pouch microcirculation. Am J Physiol Heart Circ Physiol 288:H1931–H1936. doi:10.1152/ajpheart.00931.2004 PubMed

39.

Mizuma H, Murakami M, Mori M (2001) Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase. Circ Res 88:313–318PubMed

40.

Fukuyama K, Ichiki T, Takeda K et al (2003) Downregulation of vascular angiotensin II type 1 receptor by thyroid hormone. Hypertension 41:598–603. doi:10.1161/01.HYP.0000056524.35294.80 PubMed

41.

Fommei E, Iervasi G (2002) The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 87:1996–2000. doi:10.1210/jc.87.5.1996 PubMed

42.

Dernellis J, Panaretou M (2002) Effects oh thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism. Am Heart J 143:718–724. doi:10.1067/mhj.2002.120766 PubMed

43.

Biondi B, Palmieri EA, Lombardi G et al (2002) Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab 87:968–974. doi:10.1210/jc.87.3.968 PubMed

44.

Kimura K, Shinozaki Y, Jujo S (2006) Triiodothyronine acutely increases blood flow in the ventricles and kidneys of anesthesized rabbits. Thyroid 16:357–360. doi:10.1089/thy.2006.16.357 PubMed

45.

Yoneda K, Takasu N, Higa S et al (1998) Direct effects of thyroid hormones on rat coronary artery: nongenomic effects of triiodothyronine and thyroxine. Thyroid 8:609–613PubMed

46.

Kasahara T, Tsunekawa K, Seki K et al (2006) Regulation of iodothyronine deiodinase and roles of thyroid hormones in human coronary artery smooth muscle cells. Atherosclerosis 18:207–214. doi:10.1016/j.atherosclerosis.2005.07.018

47.

Baycan S, Erdogan D, Caliskan M et al (2007) Coronary flow reserve is impaired in subclinical hypothyroidism. Clin Cardiol 30:562–566. doi:10.1002/clc.20132 PubMed

48.

Danzi S, Klein I (2004) Thyroid hormone and the cardiovascular system. Minerva Endocrinol 29:139–150PubMed

49.

Bengel FM, Nekolla S, Ziegler SI et al (2000) Effect of thyroid hormones on cardiac function and oxidative metabolism assessed noninvasively by positron emission tomography and magnetic resonance imaging. J Clin Endocrinol Metab 85:1822–1827. doi:10.1210/jc.85.5.1822 PubMed

50.

Biondi B, Palmieri EA, Lombardi G et al (2002) Subclinical hypothyroidism and cardiac function. Thyroid 12:505–510. doi:10.1089/105072502760143890 PubMed

51.

Ripoli A, Pingitore A, Favilli B et al (2005) Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study. J Am Coll Cardiol 45:439–445. doi:10.1016/j.jacc.2004.10.044 PubMed

52.

Rodondi N, Newman AB, Vittinghoff E et al (2005) Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 165:2460–2466. doi:10.1001/archinte.165.21.2460 PubMed

53.

Kahaly GJ (2000) Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 10:665–679. doi:10.1089/10507250050137743 PubMed

54.

Taddei S, Caraccio N, Virdis A et al (2003) Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 88:3731–3737. doi:10.1210/jc.2003-030039 PubMed

55.

Monzani F, Caraccio N, Kozàkowà M et al (2004) Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study. J Clin Endocrinol Metab 89:2099–2106. doi:10.1210/jc.2003-031669 PubMed

56.

Caraccio N, Ferrannini E, Monzani F (2002) Lipoprotein profile in subclinical hypothyroidism: response to replacement, a randomized placebocontrolled study. J Clin Endocrinol Metab 87:1533–1538. doi:10.1210/jc.87.4.1533 PubMed

57.

Chen HS, Wu TE, Jap TS et al (2007) Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in Type 2 diabetic patients. Diabet Med 24:1336–1344. doi:10.1111/j.1464-5491.2007.02270.x PubMed

58.

Chonchol M, Lippi G, Salvagno G, Zoppini G, Muggeo M, Targher G (2008) Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol 5:1296–1300

59.

Hak AE, Pols HA, Visser TJ et al (2000) Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med 15(132):270–278

60.

Rodondi N, Aujesky D, Vittinghoff E et al (2006) Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis. Am J Med 119:541–551. doi:10.1016/j.amjmed.2005.09.028 PubMed

61.

Sawin CT, Geller A, Wolf PA et al (1994) Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older patients. N Engl J Med 331:1249–1252. doi:10.1056/NEJM199411103311901 PubMed

62.

Osman F, Gammage MD, Sheppard MC et al (2002) Clinical review 142: cardiac dysrhythmias and thyroid dysfunction: the hidden menace? J Clin Endocrinol Metab 87:963–967. doi:10.1210/jc.87.3.963 PubMed

63.

Petretta M, Bonaduce D, Spinelli L et al (2001) Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol 145:691–696. doi:10.1530/eje.0.1450691 PubMed

64.

Biondi B, Palmieri EA, Fazio S et al (2000) Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 85:4701–4705. doi:10.1210/jc.85.12.4701 PubMed

65.

Biondi B, Palmieri EA, Lombardi G et al (2002) Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 137:904–914PubMed

66.

Mercuro G, Panzuto MG, Bina A et al (2000) Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 85:159–164. doi:10.1210/jc.85.1.159 PubMed

67.

Parle JV, Maisonneuve P, Sheppard MC et al (2001) Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358:861–865. doi:10.1016/S0140-6736(01)06067-6 PubMed

68.

Surks MI, Ortiz E, Daniels GH et al (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. J Am Med Assoc 291:228–238. doi:10.1001/jama.291.2.228

69.

Singh S, Duggal J, Molnar J et al (2008) Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol 125:41–48. doi:10.1016/j.ijcard.2007.02.027 PubMed

70.

Cappola AR, Fried LP, Arnold AM et al (2006) Thyroid status, cardiovascular risk, and mortality in older adults. J Am Med Assoc 295:1033–1041. doi:10.1001/jama.295.9.1033

71.

Imaizumi M, Akahoshi M, Ichimaru S et al (2004) Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 89:3365–3370. doi:10.1210/jc.2003-031089 PubMed

72.

Walsh JP, Bremner AP, Bulsara MK et al (2005) Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 165:2467–2472. doi:10.1001/archinte.165.21.2467 PubMed

73.

Asvold BO, Bjøro T, Nilsen TI et al (2008) Thyrotropin levels and risk of fatal coronary heart disease: the HUNT Study. Arch Intern Med 168:855–860. doi:10.1001/archinte.168.8.855 PubMed

74.

Eisenstein Z, Hagg S, Vagenakis AG et al (1978) Effect of starvation on the production and peripheral metabolism of 3, 3′, 5′-triiodothyronine in euthyroid obese subjects. J Clin Endocrinol Metab 47:889–893PubMed

75.

Eber B, Schumacher M, Langsteger W et al (1995) Changes in thyroid hormone parameters after acute myocardial infarction. Cardiology 86:152–156PubMed

76.

Friberg L, Werner S, Eggertsen G et al (2002) Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina? Arch Intern Med 162:1388–1394. doi:10.1001/archinte.162.12.1388 PubMed

77.

Holland FW 2nd, Brown PS Jr, Weintraub BD et al (1991) Cardiopulmonary bypass and thyroid function: a “euthyroid sick syndrome”. Ann Thorac Surg 52:46–50PubMed

78.

Klemperer JD, Klein I, Gomez M et al (1955) Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 333:1522–1527. doi:10.1056/NEJM199512073332302

79.

Murzi B, Iervasi G, Masini S et al (1995) Thyroid hormones homeostasis in pediatric patients during and after cardiopulmonary bypass. Ann Thorac Surg 59:481–485. doi:10.1016/0003-4975(94)00879-C PubMed

80.

Sabatino L, Cerillo AG, Ripoli A et al (2002) Is the low tri-iodothyronine state a crucial factor in determining the outcome of coronary artery bypass patients? Evidence from a clinical pilot study. J Endocrinol 175:577–586. doi:10.1677/joe.0.1750577 PubMed

81.

Wartofsky L, Barman KD (1982) Alteration in thyroid function in patients with systemic illness: the “euthyroid sick syndrome”. Endocr Rev 3:164–217PubMed

82.

Peeters RP, Wouters PJ, Kaptein E et al (2003) Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 88:3202–3211. doi:10.1210/jc.2002-022013 PubMed

83.

Chopra IJ, Wu SY, Teco GN et al (1992) A radioimmunoassay for measurement of 3, 5, 3′-triiodothyronine sulfate: studies in thyroidal and nonthyroidal diseases, pregnancy, and neonatal life. J Clin Endocrinol Metab 1:189–194. doi:10.1210/jc.75.1.189

84.

Peeters RP, Kester MH, Wouters PJ et al (2005) Increased thyroxine sulfate levels in critically ill patients as a result of a decreased hepatic type I deiodinase activity. J Clin Endocrinol Metab 90:6460–6465. doi:10.1210/jc.2005-0866 PubMed

85.

Duntas LH, Nguyen TT, Keck FS et al (1999) Changes in metabolism of TRH in euthyroid sick syndrome. Eur J Endocrinol 141:337–341. doi:10.1530/eje.0.1410337 PubMed

86.

Boelen A, Platvoet-Ter Schiphorst MC, Wiersinga WM (1993) Association betxeen serum interleukin-6 and serum 3, 5, 3′- triiodothyronine in nonthyroidal illness. J Clin Endocrinol Metab 77:1695–1699. doi:10.1210/jc.77.6.1695 PubMed

87.

Stouthard JM, Van der Poll T, Ebdert E et al (1994) Effects of acute and chronic IL-6 administration on thyroid hormone metabolism in humans. J Clin Endocrinol Metab 79:1342–1346. doi:10.1210/jc.79.5.1342 PubMed

88.

Bartalena L, Bogazzi F, Brogioni S et al (1998) Role of cytokines in the pathogenesis of the euthyroid sick syndrome. Eur J Endocrinol 138:603–614. doi:10.1530/eje.0.1380603 PubMed

89.

Kimura T, Kanda T, Kotajima N et al (2000) Involvment of circulating IL-6 and its receptor in the development o euthyroid sick syndrome in patients with acute myocardial infarction. Eur J Endocrinol 143:179–184. doi:10.1530/eje.0.1430179 PubMed

90.

Reichlin S (1993) Neuroendocrine-Immune interactions. N Engl J Med 329:1246–1253. doi:10.1056/NEJM199310213291708 PubMed

91.

Sylvén C, Jansson E, Sotonyi P et al (1996) Cardiac nuclear hormone receptor mRNA in heart failure in man. Life Sci 59:1917–1922. doi:10.1016/S0024-3205(96)00539-5 PubMed

92.

Kinugawa K, Yonekura K, Ribeiro RC et al (2001) Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res 89:591–598. doi:10.1161/hh1901.096706 PubMed

93.

Liu Y, Redetzke RA, Said S et al (2008) Serum thyroid hormone levels may not accurately reflect thyroid tissue levels and cardiac function in mild hypothyroidism. Am J Physiol Heart Circ Physiol 294:H2137–H2143. doi:10.1152/ajpheart.01379.2007 PubMed

94.

Sabatino L, Gliozheni E, Molinaro S et al (2007) Thyroid hormone receptor and IGF1/IGFR systems: possible relations in the human heart. Biomed Pharmacother 61:457–462. doi:10.1016/j.biopha.2007.04.002 PubMed

95.

Belke DD, Gloss B, Swanson EA et al (2007) Adeno-associated virus-mediated expression of thyroid hormone receptor isoforms-alpha1 and -beta1 improves contractile function in pressure overload-induced cardiac hypertrophy. Endocrinology 148:2870–2877. doi:10.1210/en.2007-0009 PubMed

96.

Mai W, Janier MF, Allioli N et al (2004) Thyroid hormone receptor alpha is a molecular switch of cardiac function between fetal and postnatal life. Proc Natl Acad Sci USA 101:10332–10337. doi:10.1073/pnas.0401843101 PubMed

97.

Kinugawa K, Minobe WA, Wood WM et al (2001) Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation 103:1089–1094PubMed

98.

Izumo S, Lompré AM, Matsuoka R et al (1987) Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest 79:970–977. doi:10.1172/JCI112908 PubMed

99.

Colucci WS (1997) Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 80:15L–25L. doi:10.1016/S0002-9149(97)00845-X PubMed

100.

Haghighi K, Schmidt AG, Hoit BD et al (2001) Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J Biol Chem 276:24145–24152. doi:10.1074/jbc.M102403200 PubMed

101.

Razeghi P, Young ME, Alcorn JL et al (2001) Metabolic gene expression in fetal and failing human heart. Circulation 104:2923–2931. doi:10.1161/hc4901.100526 PubMed

102.

Katzeff HL, Powell SR, Ojamaa K (1997) Alterations in cardiac contractility and gene expression during low-T3 syndrome: prevention with T3. Am J Physiol 273:E951–E956PubMed

103.

Ladenson PW, Sherman SI, Baughman KL et al (1992) Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci USA 89:5251–5255. doi:10.1073/pnas.89.12.5251 PubMed

104.

Forini F, Paolicchi A, Pizzorusso T et al (2001) 3, 5, 3′-Triiodothyronine deprivation affects phenotype and intracellular [Ca2 +]i of human cardiomyocytes in culture. Cardiovasc Res 51:322–330. doi:10.1016/S0008-6363(01)00287-5 PubMed

105.

Pieske B, Kretschmann B, Meyer M et al (1995) Alteration in intracellular calcium handling associated with the inverse force frequency relation in human dilated cardiomyopathy. Circulation 92:1169–1178PubMed

106.

Hein S, Kostin S, Heling A et al (2000) The role of cytoskeleton in heart failure. Cardiovasc Res 45:273–278. doi:10.1016/S0008-6363(99)00268-0 PubMed

107.

Pantos C, Xinaris C, Mourouzis I et al (2007) Thyroid hormone changes cardiomyocyte shape and geometry via ERK signaling pathway: potential therapeutic implications in reversing cardiac remodeling? Mol Cell Biochem 297:65–72. doi:10.1007/s11010-006-9323-3 PubMed

108.

Lee HW, Klein LE, Raser J et al (1998) An activator protein-1 (AP-1) response element on pro alpha1(l) collagen gene is necessary for thyroid hormone-induced inhibition of promoter activity in cardiac fibroblasts. J Mol Cell Cardiol 30:2495–2506. doi:10.1006/jmcc.1998.0811 PubMed

109.

Yao J, Eghbali M (1992) Decreased collagen mRNA and regression of cardiac fibrosis in the ventricular myocardium of the tight skin mouse following thyroid hormone treatment. Cardiovasc Res 26:603–607. doi:10.1093/cvr/26.6.603 PubMed

110.

Wong K, Boheler KR, Petrou M (1997) Pharmacological modulation of pressure-overload cardiac hypertrophy: changes in ventricular function, extracellular matrix, and gene expression. Circulation 96:2239–2246PubMed

111.

Janicki JS, Brower GL, Gardner JD et al (2004) The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail Rev 9:33–42. doi:10.1023/B:HREV.0000011392.03037.7e PubMed

112.

Khalife WI, Tang YD, Kuzman JA et al (2005) Treatment of subclinical hypothyroidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289:H2409–H2415. doi:10.1152/ajpheart.00483.2005 PubMed

113.

Ryoke T, Gu Y, Ikeda Y et al (2002) Apoptosis and oncosis in the early progression of left ventricular dysfunction in the cardiomyopathic hamster. Basic Res Cardiol 97:65–75. doi:10.1007/s395-002-8389-4 PubMed

114.

Tomanek RJ, Schatteman GC (2000) Angiogenesis: new insights and therapeutic potential. Anat Rec 261:126–135. doi:10.1002/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4PubMed

115.

Wang X, Zheng W, Christensen LP et al (2003) DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth. Am J Physiol Heart Circ Physiol 284:H613–H618PubMed

116.

Zheng W, Weiss RM, Wang X et al (2004) DITPA stimulates arteriolar growth and modifies myocardial postinfarction remodeling. Am J Physiol Heart Circ Physiol 286:H1994–H2000. doi:10.1152/ajpheart.00991.2003 PubMed

117.

Davis FB, Mousa SA, O’Connor L et al (2004) Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 94:1500–1506. doi:10.1161/01.RES.0000130784.90237.4a PubMed

118.

van den Heuvel AF, van Veldhuisen DJ, van der Wall EE et al (2000) Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 35:19–28. doi:10.1016/S0735-1097(99)00499-4 PubMed

119.

Neglia D, Michelassi C, Trivieri MG et al (2002) Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 15:186–193. doi:10.1161/hc0202.102119

120.

Pantos C, Malliopoulou V, Varonos DD et al (2003) Thyroid hormone and phenotypes of cardioprotection. Basic Res Cardiol 99:101–120. doi:10.1007/s00395-003-0449-0 PubMed

121.

Liu Q, Clanachan AS, Lopaschuk GD (1998) Acute effects of triiodothyronine on glucose and fatty acid metabolism during reperfusion of ischemic rat hearts. Am J Physiol 275:E392–E399PubMed

122.

Chen YF, Kobayashi S, Chen J et al (2008) Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats. J Mol Cell Cardiol 44:180–187. doi:10.1016/j.yjmcc.2007.09.009 PubMed

123.

Pantos C, Malliopoulou V, Mourouzis I et al (2003) Thyroxine pretreatment increases basal myocardial heat-shock protein 27 expression and accelerates translocation and phosphorylation of this protein upon ischaemia. Eur J Pharmacol 478:53–60. doi:10.1016/j.ejphar.2003.08.030 PubMed

124.

Pantos C, Malliopoulou V, Mourouzis I et al (2006) Hyperthyroid hearts display a phenotype of cardioprotection against ischemic stress: a possible involvement of heat shock protein 70. Horm Metab Res 38:308–313. doi:10.1055/s-2006-925404 PubMed

125.

Giannessi D, Colotti C, Maltinti M et al (2007) Circulating heat shock proteins and inflammatory markers in patients with idiopathic left ventricular dysfunction: their relationships with myocardial and microvascular impairment. Cell Stress Chaperones 12:265–274. doi:10.1379/CSC-272.1 PubMed

126.

Emdin M, Passino C, Prontera C et al (2004) Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 42:627–636. doi:10.1515/CCLM.2004.108 PubMed

127.

Pingitore A, Iervasi G (2008) Triiodothyronine (T3) effects on cardiovascular system in patients with heart failure. Recent Patents Cardiovasc Drug Discov 3:19–27

128.

Chopra IJ (1997) Euthyroid sick syndrome: is it a misnomer? J Clin Endocrinol Metab 82:329–334. doi:10.1210/jc.82.2.329 PubMed

129.

De Groot LJ (1999) Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab 84:151–164. doi:10.1210/jc.84.1.151 PubMed

130.

Klein I, Danzi S (2008) Thyroid hormone treatment to mend a broken heart. J Clin Endocrinol Metab 93:1172–1174. doi:10.1210/jc.2008-0291 PubMed

131.

Pantos C, Mourouzis I, Markakis K et al (2007) Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats. Eur J Cardiothorac Surg 32:333–339. doi:10.1016/j.ejcts.2007.05.004 PubMed

132.

Brokhin M, Klein I (2005) Low T3 syndrome in a patient with acute myocarditis. Clin Cornerstone 7(Suppl 2):S28–S29. doi:10.1016/S1098-3597(05)80057-2 PubMed

133.

Malik FS, Mehra MR, Uber PA et al (1999) Intravenous thyroid hormone supplementation in heart failure with cardiogenic shock. J Card Fail 5:31–37. doi:10.1016/S1071-9164(99)90022-2 PubMed

134.

Klemperer JD, Zelano J, Helm RE et al (1995) Triiodothyronine improves left ventricular function without oxygen wasting effects after global hypothermic ischemia. J Thorac Cardiovasc Surg 109:457–465. doi:10.1016/S0022-5223(95)70276-8 PubMed

135.

Klemperer JD, Klein IL, Ojamaa K et al (1996) Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations. Ann Thorac Surg 61:1323–1327. doi:10.1016/0003-4975(96)00102-6 PubMed

136.

Moruzzi P, Doria E, Agostoni PG et al (1994) Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol 73:374–378. doi:10.1016/0002-9149(94)90011-6 PubMed

137.

Moruzzi P, Doria E, Agostoni PG (1996) Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med 101:461–467. doi:10.1016/S0002-9343(96)00281-1 PubMed

138.

Hamilton MA, Stevenson LW, Fonarow GC et al (1998) Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol 81:443–447. doi:10.1016/S0002-9149(97)00950-8 PubMed

139.

Pingitore A, Galli E, Barison A et al (2008) Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 93:1351–1358. doi:10.1210/jc.2007-2210 PubMed

140.

Brenta G, Danzi S, Klein I (2007) Potential therapeutic applications of thyroid hormone analogs. Nat Clin Pract Endocrinol Metab 3:632–640. doi:10.1038/ncpendmet0590 PubMed

141.

Pennock GD, Raya TE, Bahl JJ et al (1992) Cardiac effects of 3, 5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity. J Pharmacol Exp Ther 263:163–169PubMed

142.

Morkin E, Pennock GD, Spooner PH et al (2002) Clinical and experimental studies on the use of 3, 5-diiodothyropropionic acid, a thyroid hormone analogue, in heart failure. Thyroid 12:527–533. doi:10.1089/105072502760143935 PubMed

143.

Morkin E, Ladenson P, Goldman S et al (2004) Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects. J Mol Cell Cardiol 37:1137–1146PubMed

144.

Trivieri MG, Oudit GY, Sah R et al (2006) Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proc Natl Acad Sci USA 103:6043–6048. doi:10.1073/pnas.0601072103 PubMed

Title: The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence
Authors: E. Galli
A. Pingitore
G. Iervasi
Publication date: 01-03-2010
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 2/2010
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-008-9126-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Cardiomyocyte-specific inactivation of thyroid hormone in pathologic ventricular hypertrophy: an adaptative response or part of the problem?

Cardiac effects of thyronamines

Use of a new model of transgenic mice to clarify the respective functions of thyroid hormone receptors in vivo

The role of thyroid hormone nuclear receptors in the heart: evidence from pharmacological approaches

Physiological consequences of the TRα1 aporeceptor state

Cardiac hypertrophy and thyroid hormone signaling